TapewireFind a company

person · Reporting owner

Hindson Benjamin J.

Disclosed activity across 1 company

Tapewire entity
19364
SEC CIK
0001786391

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
10x Genomics, Inc.TXG · Entity 2172Director · See RemarksAugust 24, 2026August 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

10x Genomics, Inc.

Report date August 24, 2026 · Filed August 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect488,182 Reported balance After 2026-08-24 transaction · row 1
1 source row

Row 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182

F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 03, 2021 Filed May 5, 2021 21:10 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 24,080 $1.07 $25,765.60
Disclosure

SEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 41,666 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · derivative · entry 9

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,032

Underlying: Class A Common Stock · 41,666 shares

Expires 2026-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F9 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 300 $186.08 $55,823.49
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 8

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,636

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · price: This transaction was executed in multiple trades at prices ranging from $186.005 to $186.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 14,632 $185.52 $2,714,562.29
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,936

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $185.02 to $185.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 16,748 $184.53 $3,090,521.84
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,568

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $184.02 to $185.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 6,686 $183.74 $1,228,511.05
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,316

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $183.02 to $184.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,900 $182.48 $346,703.07
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,002

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $181.96 to $182.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 600 $181.50 $108,900.00
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,902

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $180.96 to $181.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 800 $179.98 $143,986.00
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,502

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $179.80 to $180.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2021 Filed Apr 2, 2021 21:19 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 41,666 $1.07 $44,582.62
Disclosure

SEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,302

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
March 19, 2021 Filed May 27, 2021 00:25 UTC 10x Genomics, Inc. TXG · Entity 2172 GrantStock Option (right to buy) · Derivative 27,922 $0.00 Strike: $177.76 $0.00
Disclosure

SEC source: 0001209191-21-036101 · doc4.xml · derivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,922

Underlying: Class A Common Stock · 27,922 shares

Expires 2031-03-19

F5 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
March 19, 2021 Filed May 27, 2021 00:25 UTC 10x Genomics, Inc. TXG · Entity 2172 GrantClass A Common Stock 11,169 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-036101 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,805

F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: The number of shares beneficially owned following the reported transaction is as of March 19, 2021.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 5,302 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · derivative · entry 10

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,698

Underlying: Class A Common Stock · 5,302 shares

Expires 2026-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F9 · derivative.exercise_date: This option, originally for 125,000 shares, of which 5,302 shares have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 36,364 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · derivative · entry 9

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 36,364 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,167 $159.40 $1,142,386.12
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 8

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,636

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $159.03 to $159.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 6,368 $158.64 $1,010,222.70
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,803

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $158.02 to $159.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 5,845 $157.48 $920,451.90
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,171

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $157.02 to $158.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,189 $156.45 $1,281,142.85
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,016

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $156.005 to $156.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,074 $155.54 $1,255,814.62
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,205

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $155.01 to $156.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 6,023 $154.56 $930,887.17
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,279

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $154.00 to $154.985. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 5,302 $1.07 $5,673.14
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,302

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:52 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 36,364 $0.88 $32,000.32
Disclosure

SEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 607 $179.01 $108,661.86
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,636

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $178.86 to $179.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,998 $177.68 $532,671.45
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,243

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $177.36 to $178.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 6,322 $176.65 $1,116,780.67
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,241

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $176.25 to $177.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 18,374 $175.74 $3,229,090.86
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,563

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $175.25 to $176.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,749 $174.90 $830,601.05
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,937

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $174.24 to $175.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 01:08 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 700 $173.79 $121,649.99
Disclosure

SEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,686

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $173.21 to $174.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:12 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,200 $141.58 $169,896.48
Disclosure

SEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,386

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $141.315 to $142.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:12 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 6,825 $140.62 $959,744.47
Disclosure

SEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,586

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $140.28 to $141.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:12 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 22,026 $139.83 $3,079,814.08
Disclosure

SEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,411

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $139.27 to $140.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:12 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,699 $138.78 $513,345.74
Disclosure

SEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,437

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $138.265 to $139.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 24, 2020 Filed Dec 28, 2020 23:13 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 28,000 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-20-065242 · doc4.xml · derivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,000

Underlying: Class A Common Stock · 28,000 shares

Expires 2027-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option, originally for 200,000 shares, of which 28,000 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
December 24, 2020 Filed Dec 28, 2020 23:13 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 8,636 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-065242 · doc4.xml · derivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,364

Underlying: Class A Common Stock · 8,636 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
December 24, 2020 Filed Dec 28, 2020 23:13 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 28,000 $1.20 $33,600.00
Disclosure

SEC source: 0001209191-20-065242 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 24, 2020 Filed Dec 28, 2020 23:13 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 8,636 $0.88 $7,599.68
Disclosure

SEC source: 0001209191-20-065242 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 33,750 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · derivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Class A Common Stock · 33,750 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,835 $153.68 $435,682.23
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 6

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $153.45 to $154.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,700 $153.14 $719,771.63
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 5

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,335

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $152.44 to $153.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,619 $151.84 $701,333.72
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 4

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,035

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $151.41 to $152.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 11,113 $150.92 $1,677,222.86
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 3

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,654

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $150.41 to $151.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 10,483 $150.07 $1,573,137.68
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 2

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,767

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $149.41 to $150.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 33,750 $0.88 $29,700.00
Disclosure

SEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 1

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 12,688 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · derivative · entry 13

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,750

Underlying: Class A Common Stock · 12,688 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F11 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 295 $138.49 $40,854.90
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 11

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F10 · price: This transaction was executed in multiple trades at prices ranging from $138.20 to $138.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,353 $137.57 $1,011,559.56
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 10

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,795

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F9 · price: This transaction was executed in multiple trades at prices ranging from $137.11 to $138.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,642 $136.62 $634,209.54
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 9

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,148

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · price: This transaction was executed in multiple trades at prices ranging from $136.09 to $137.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 398 $135.52 $53,935.97
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 8

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,790

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $135.07 to $135.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 03, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 12,688 $0.88 $11,165.44
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 7

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
November 02, 2020 Filed Nov 5, 2020 02:34 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 21,062 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001209191-20-057067 · doc4.xml · derivative · entry 12

Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,438

Underlying: Class A Common Stock · 21,062 shares

Expires 2025-10-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F11 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.